Amgen, Sanofi to Fight Over Enhanced Damages in Blockbuster Infringement Row
A Delaware federal judge has allowed Amgen Inc. to pursue enhanced damages in its patent infringement dispute with a rival drugmaker, the latest development to a case with billions of dollars on the line.
This premium content is reserved for Delaware Law Weekly subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now